Powered by MedShift
A Nonsurgical Solution
for Your Acquired Ptosis Patients
Low-lying lids may be caused by acquired blepharoptosis. If you see signs of low-lying lids in your patients, talk to them about getting UPLIFTED with Upneeq!
About Acquired Blepharoptosis (Low-Lying Lids)
A common eyelid disorder that can impact adults of all ages, not just those over age 50.
• Can make eyes appear tired/sleepy/droopy, or make one eyelid visibly lower than the other
• May cause vision impairment, interfering with day-to-day functions (reading, driving, computer use)
Why it’s important to check patients’ eyelids and
start a dialogue
Patients may not bring up concerns about low-lying lids because they:
• May hesitate to bring up an “appearance” concern
• Do not know the cause may be a medical condition
• May think there are no topical prescription treatment options
give your ptosis patients an eye-opening lift with a daily drop of upneeq®: the only fda-approved prescription eyedrop proven to lift upper eyelids in adults with acquired blepharoptosis (low-lying lids).
UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1% is indicated for the treatment of acquired blepharoptosis in adults.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
• Ptosis may be associated with neurologic or orbital diseases such as stroke and/or cerebral aneurysm, Horner syndrome, myasthenia gravis, external ophthalmoplegia, orbital infection and orbital masses. Consideration should be given to these conditions in the presence of ptosis with decreased levator muscle function and/or other neurologic signs.
• Alpha-adrenergic agonists as a class may impact blood pressure. Advise UPNEEQ patients with cardiovascular disease, orthostatic hypotension, and/or uncontrolled hypertension or hypotension to seek medical care if their condition worsens.
• Use UPNEEQ with caution in patients with cerebral or coronary insufficiency or Sjögren’s syndrome. Advise patients to seek medical care if signs and symptoms of potentiation of vascular insufficiency develop.
• UPNEEQ may increase the risk of angle closure glaucoma in patients with untreated narrow-angle glaucoma. Advise patients to seek immediate medical care if signs and symptoms of acute narrow-angle glaucoma develop.
Patients should not touch the tip of the single patient-use container to their eye or to any surface, in order to avoid eye injury or contamination of the solution.
Adverse reactions that occurred in 1-5% of subjects treated with UPNEEQ were punctate keratitis, conjunctival hyperemia, dry eye, blurred vision, instillation site pain, eye irritation and headache.
• Alpha-adrenergic agonists, as a class, may impact blood pressure. Caution in using drugs such as beta blockers, anti-hypertensives, and/or cardiac glycosides is advised. Caution should also be exercised in patients receiving alpha adrenergic receptor antagonists such as in the treatment of cardiovascular disease, or benign prostatic hypertrophy.
• Caution is advised in patients taking monoamine oxidase inhibitors which can affect the metabolism and uptake of circulating amines.
To report SUSPECTED ADVERSE REACTIONS or product complaints, contact RVL Pharmaceuticals at 1-877-482-3788. You may also report SUSPECTED ADVERSE REACTIONS to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.